Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 9,325 citations
https://doi.org/10.1056/nejmoa1507643
N
Naiyer A. Rizvi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
470
Papers
64.8K
Citations
81
h-index
222
i10-index
Naiyer A. Rizvi is an academic researcher from Western University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics. The author has an h-index of 81, co-authored 400 publications.
ORCID: 0000-0002-1134-7494Papers by this author
worksMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
2015 · Science · 7,818 citations
https://doi.org/10.1126/science.aaa1348
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
2015 · New England Journal of Medicine · 6,155 citations
https://doi.org/10.1056/nejmoa1501824
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
2019 · Nature Genetics · 4,300 citations
https://doi.org/10.1038/s41588-018-0312-8
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
2016 · Science · 3,032 citations
https://doi.org/10.1126/science.aaf1490
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
2017 · Science · 1,147 citations
https://doi.org/10.1126/science.aao4572
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat